The company’s latest offering empowers clinical trial sponsors to harness the full potential of their biospecimen data, transforming it into actionable insights throughout the trial process, from startup to closeout.
Mark Melton, vice president of biospecimen data and operations at Slope, emphasized the added value of these services: “Our sponsor customers of Slope’s biospecimen lifecycle software, Biospecimen360, already receive guidance from our team of experts along every touchpoint of the biospecimen lifecycle. Our new tech-enabled services elevate this support, ensuring our sponsors are actualizing the immense value of their sample data.”
The launch of Slope’s new professional services provides a customizable range of offerings that extend beyond the initial setup and execution phases, offering deep, specialized expertise across biospecimen operations. By supporting various critical functions, these services ensure that sponsors can streamline processes and improve overall trial efficiency.
Key areas supported by Slope’s tech-enabled services include:
Lab and biospecimen operations: Slope offers expert guidance on protocol design, vendor selection, and sample collection workflows. This strategic and operational oversight helps clinical trial sponsors streamline trial execution while maintaining quality standards and adhering to critical timelines.
End-to-end sample tracking: Slope delivers comprehensive monitoring and reconciliation of biospecimen movement and metadata. These services provide real-time tracking throughout the entire biospecimen lifecycle, minimizing deviations and ensuring the integrity of the samples. This helps sponsors stay on top of their sample inventory and maintain high-quality data throughout the trial process.
Biospecimen data management: From study setup through final database lock, Slope oversees all aspects of sample metadata. The company’s services ensure data governance, integrity, and seamless transfers, essential for maintaining the quality of the trial and ensuring that protocol endpoints are met. Rigorous data management ensures that sponsors can make well-informed decisions based on real-time, accurate information.
Melton added, “We recognize the profound impact of controlling kit inventory, sample collection, processing, and shipment in a single platform on all stakeholders involved in a clinical trial. With Slope’s new suite of services, you don’t just get quicker access to more high-quality data — you get the expertise to optimize your data and transform that data into actionable insights — driving better decisions and more efficient trials.”
Slope says its tech-enabled services provide a cost-effective, high-impact solution for pharmaceutical companies facing the growing complexities of sample-intensive trials. By combining its core product, Biospecimen360, with expert support, the company says it empowers clinical trial sponsors to unlock the full potential of their biospecimen data. These services not only enhance the quality and speed of data access but also drive efficiency and ensure that every decision made during a trial is backed by the highest-quality, real-time information.
The new services also reflect the company’s broader mission of helping pharmaceutical companies tackle the intricate challenges associated with modern clinical trials. As trials become more complex and sample-intensive, having robust biospecimen lifecycle management capabilities becomes crucial. By providing comprehensive data management and operational support, Slope aims to transform how biospecimen data is handled and used in clinical trials, ultimately improving trial outcomes.
